Insider buying last 90 days
No open-market insider purchases were filed for AMRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Amneal Pharmaceuticals rose this week after third-quarter 2026 results topped estimates, with net revenue up 10% to $863 million and adjusted EBITDA up 30% to $207 million. Adjusted EPS came in at $0.26 against a $0.24 estimate, with earnings of $0.17 per share a year ago cited for comparison, as growth in Affordable Medicines and Specialty products offset an expected decline at AvKARE. The company also raised its full-year 2026 guidance following the beat.
Shares closed at $21.28, up 5.7%, sitting above both the 50-day average of $19.41 and the 200-day average of $15.95, with the 50-day above the 200-day. The stock trades near its 52-week high of $21.68, well above its 52-week low of $11.29. The GekkoIndex reads 52.9, placing it in the Neutral zone, and the price sits 12.7% above the Gekko Fair Value of $18.88.
The next earnings date falls on 26 February 2027, 108 days out and beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in their respective windows. All six covering analysts carry a buy rating, with a consensus target of $23.43 implying 10.1% upside from current levels. Seasonality over the next 20 trading days has averaged -1% across 5 years, rising in 4 of them, a mixed historical pattern worth noting alongside the stock's recent strength relative to its moving averages.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Amneal Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Above 50 and 200-day
Close $21.38 is above the 50-day ($19.71) and 200-day ($16.10) averages, and the 50-day is above the 200-day.
See the chart51.4, Neutral
Reading 51.4 is in the Neutral zone.
See the GekkoIndex13.8% above
Price is 13.8% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 103 days
Next report Feb 26, 2027, 103 days away — outside a typical 20-trading-day hold.
See earnings−4.1% on average
From this point in the calendar, the next 20 trading days averaged −4.1% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Amneal Pharmaceuticals closed at $21.38 on Nov 13, 2026, +79.7% over the past year, inside a 52-week range of $11.39 to $22.07.
Use the left and right arrow keys to read daily values.
Put AMRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Amneal Pharmaceuticals develops, licenses, manufactures, markets and distributes both generic and branded medicines across many delivery forms, addressing a wide range of treatment needs. It works with dosage types such as tablets, injectables, eye drops, liquids, topical treatments, softgels, inhalants and patches, and its branded lineup includes Emverm for parasitic infections, Rytary for Parkinson's disease, and Unithroid for hypothyroidism.
The business runs through three segments. Generics covers the creation and sale of complex drug formulations. Specialty focuses on developing and marketing proprietary branded medicines, with emphasis on neurological, endocrine and parasitic conditions. AvKARE supplies pharmaceuticals and medical and surgical goods to government bodies, notably the Department of Defense and the Department of Veterans Affairs, and also handles bulk packaging and distribution of medicines and supplements under the AvKARE and AvPAK names for retail and institutional buyers. Products move through wholesalers, distributors, hospitals, pharmacy chains and independent drugstores, with activity spanning the United States, India, Ireland and other markets.
Amneal traces back to 2002, when it was set up as Atlas Holdings, Inc., taking its current name in 2018. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ under the ticker AMRX.
Amneal Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.4, in the Neutral zone, down 6.8 points over five sessions.
Down 6.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 12 | +0.6% | +6.2% | ||
| Accumulation | 152 | +2.6% | +8.5% | ||
| Neutral (current zone) | 471 | +0.7% | +3.2% | ||
| Distribution | 65 | +0.5% | +2.4% | ||
| Selling | 2 | Too few readings yet | |||
Average AMRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Amneal Pharmaceuticals trades 13.8% above Gekko Fair Value of $18.79, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Amneal Pharmaceuticals shares are worth, recalculated every trading day.
$18.79
Gekko Fair Value, Nov 14, 2026
13.8% Overvalued
At the end of Aug 2026 the price was 2.6% below the estimate.
No open-market insider purchases were filed for Amneal Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for AMRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in AMRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Amneal Pharmaceuticals has been buying back its own shares.
From company filings.
Amneal Pharmaceuticals reports on Feb 26, 2027, before the open (103 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 26, 2027
Expected before the open, 103 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.27 est $0.24 | $796.2M est $768.2M | −4.1% |
| May 7, 2026 | $0.27 est $0.19 | $722.5M est $719.7M | −3.1% |
| Feb 27, 2026 | $0.21 est $0.18 | $814.3M est $807.4M | −5.0% |
| Oct 30, 2025 | $0.17 est $0.13 | $784.5M est $806.1M | +3.7% |
| Aug 5, 2025 | $0.25 est $0.18 | $724.5M est $768.6M | +1.1% |
| May 2, 2025 | $0.21 est $0.15 | $695.4M est $744.2M | −2.6% |
| Feb 28, 2025 | $0.12 est $0.15 | $730.5M est $723.1M | +4.5% |
| Nov 8, 2024 | $0.16 est $0.13 | $702.5M est $700.8M | +6.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Amneal Pharmaceuticals is $24.29, +13.6% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 6 | UBS | $28 | +31.0% |
| Nov 5 | Leerink Partners | $25 | +16.9% |
| Nov 4 | J.P. Morgan | $25 | +16.9% |
| Nov 3 | Oppenheimer | $27 | +26.3% |
| Oct 29 | Goldman Sachs | $24 | +12.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Amneal Pharmaceuticals averaged −4.1% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.6% | 1 of 5 |
| Next 10 trading days | −3.1% | 2 of 5 |
| Next 15 trading days | −3.8% | 2 of 5 |
| Next 20 trading days | −4.1% | 3 of 5 |
| Next 30 trading days | +1.9% | 2 of 5 |
For scale, AMRX’s typical 20-trading-day move in either direction is about 8.3%.
Amneal Pharmaceuticals’s market cap is $7.45B, with a P/E ratio of 54.3 and revenue of $3.20B over the last twelve months.
3 headlines about Amneal Pharmaceuticals from the past week, newest first, each linking to the publisher.
Amneal Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Amneal Pharmaceuticals’s market cap is $7.45B at the Nov 13, 2026 close of $21.38, with 348.4M shares outstanding. The shares trade on a P/E ratio of 54.3.
The consensus analyst 12-month price target for Amneal Pharmaceuticals is $24.29, +13.6% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Amneal Pharmaceuticals is overvalued: the Nov 13, 2026 close of $21.38 is 13.8% above Gekko Fair Value of $18.79. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Amneal Pharmaceuticals is expected to report on Feb 26, 2027, before the market opens (103 days away). Analysts expect earnings of $0.24 per share on revenue of $838.2M. Amneal Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 3.9% on average across the report.
Amneal Pharmaceuticals’s 52-week high is $22.07 and its 52-week low is $11.39; it closed at $21.38 on Nov 13, 2026, +79.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.